Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

NCT02004769 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Stomach Neoplasms
Neoplasms Metastasis
ERBB2 Gene Amplification

Interventions

DRUG: Trastuzumab
DRUG: Docetaxel
DRUG: Capecitabine

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]